Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

President

Chief Medical Officer

Corporate Controller

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and i...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2022-04-29	Premium	bought	Premium	Premium	Premium	-
2022-01-07	Premium	bought	Premium	Premium	Premium	President
2022-01-06	Premium	bought	Premium	Premium	Premium	Chief Medical Officer
2021-06-25	Premium	acquired	Premium	Premium	Premium	-
2021-06-25	Premium	acquired	Premium	Premium	Premium	-
2021-06-25	Premium	acquired	Premium	Premium	Premium	-
2021-06-25	Premium	acquired	Premium	Premium	Premium	President
2021-06-25	Premium	acquired	Premium	Premium	Premium	-
2021-06-25	Premium	acquired	Premium	Premium	Premium	Corporate Controller
2021-06-25	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer

TPST - Tempest Therapeutics Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for TPST